Monoclonal Antibody MS
Monoclonal Antibody Basics
Monoclonal antibodies (mAbs) are a rapidly growing class of drugs with recent successes in the treatment of cancers. mAbs are derived from identical immune cells and demonstrate a monovalent affinity toward a specific epitope, unlike polyclonal antibodies derived from multiple cell lineages and demonstrate affinity toward multiple epitopes. The development of mAbs for therapeutic and research applications, demand thorough characterization of the molecule and production method. Molecular mass, amino acid sequence, 2°, 3° and 4° structure, post-translational modifications (PTMs) including glycosylation, binding affinities and endotoxin limits are some of the important characterization parameters essential to development of a quality mAb.
mAbs belong to the larger immunoglobulin (IgG) protein family. The basic structure of mAbs consist of a complex of two light and two heavy chains connected by disulfide bridges. Each chain is divided into two major regions; a variable (V) region at the amino-terminal end and a constant (C) region at carboxyl-terminal end; the C region is frequently divided into smaller sub-regions. The sequence differences in the V region accounts for a great deal of structural diversity responsible for the target specificity of the antigen-binding cleft. Early fragmentation work by Rodney Porter and Gerald Edelman broke the IgG structure into 3 fragments using papain to cleave above the region later called the hinge region. The result was 2 identical antigen binding fragments called Fab fragments (fragments of antigen-binding) and 1 Fc fragment (fragment crystallizable). The Fc region of the mAb can interact with cellular receptors and additional proteins to form more complex multi-meric structures; depending on the sequence and glycosylation state. The majority of glycosylation on mAbs is N-linked through conserved asparagine residues (N297) in the CH2 section of the Fc region on the heavy chain. N-linked Glycans fall into 3 major types high mannose, complex and hybrid (an intermediate of high mannose and complex); with complex types being the most prevalent on mAbs. The heterogeneity of N-linked glycans on the Fc region of mAbs modulates important biological parameters, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). A thorough understanding of the glycosylation state of the Fc region is of critical importance to therapeutic mAb design and production. The cartoon below illustrates the basic structure of an IgG discussed above.
Why should you consider Novatia and ESI/LC/MS for characterization of your mAbs?
At Novatia, we use electrospray ionization liquid chromatography mass spectrometry (ESI/LC/MS) to characterize your monoclonal antibodies. Our expert team has more than 38 years of biological mass spectrometry experience. We offer rapid turnaround of high quality analysis results to meet your product specific needs, at cost-effective prices.
mAb LC/MS Analysis Services
|Features and Benefits of Novatia mAb LC/MS Services||Applications|
|Excellent mass accuracy, typically +/- 0.01% (i.e., 1 Da in 10 kDa).||Confirm MW of target mAb, with and free of glycans.|
|Methods for detailed profiling and high-throughput MW determination are available.||Identification of attached glycan and site of attachment.|
|Unparalleled ESI spectral deconvolution technology: ProMass||Identification of sequence mutations and post-translational modifications.|
|mAbs can be analyzed in high concentrations of salts, buffers and other contaminants.||Assess heterogeneity of the mAb protein and glycosylation.|
|Backed by over 38 years of experience in biological mass spectrometry.||Compare mAbs from different production lots for consistency.|
Intact MSQC4 standard mAb analysis
Molecular weight determination or confirmation of the mAb with glycans still attached. The mass is accurately determined and displayed using ProMass software to deconvolute the raw ESI spectrum.
Zoom-in of the deconvoluted peak reveals the heterogeneity of the glycosylation state of MSQC4. The table below is a screenshot of the ProMass accurate mass report including the breakdown of glycosylation state of the intact MSQC4 sample.
Deglycosylated MSQC4 standard mAb analysis
PNGase F is used to rapidly remove N-linked oligosaccharides on MSQC4 while leaving the heavy and light chain complex intact. ProMass deconvolutes the ESI spectrum and produces an artefact-free accurate mass spectrum. The table below is a screenshot of the ProMass accurate mass report.
Reduction of MSQC4 mAb standard analysis
MSQC4 is rapidly reduced while leaving the glycosylation modifications intact. The mass of the heavy and light chains are accurately determined using ProMass software to deconvolute the respective ESI spectra.
Heavy chain of MSQC4
Zoom-in of the deconvoluted peak reveals the heterogeneity of the glycosylation state of the MSQC4 heavy chain. The table below is a screenshot from the ProMass report; including a breakdown of the MSQC4 glycosylation state of the heavy chain subunits and their accurate mass.
Light chain of MSQC4
The single deconvoluted peak confirms that the light chain of MSQC4 is not glycosylated.
MS analysis of deglycosylated and reduced MSQC4 mAb standard
MSQC4 mAb standard is rapidly reduced and deglycosylated to produce the light and glycan-free heavy chains. ProMass software is used to deconvolute the ESI spectra and determine the accurate mass. The table below is a screenshot of the ProMass accurate mass report of the deglycosylated heavy chain subunits.
Deglycosylated heavy chain of MSQC4
Light chain of MSQC4
MS analysis of Fab and Fc fragments
MSQC4 mAb standard is rapidly digested in the hinge region, below the interchain disulfide bridges. The result is a large Fab fragment, consisting of a portion of the heavy chain and the light chain, and two smaller Fc fragments, containing the glycosylated portion of the heavy chain. ProMass software is used to deconvoluted the ESI spectra and determine the accurate masses of the fragments.
Zoom-in of the deconvoluted peak reveals the heterogeneity of the glycosylation state of the MSQC4 Fc fragment. The table below is a screenshot from the ProMass report; including a breakdown of the MSQC4 glycosylation state of the Fab and Fc fragments and their accurate masses.